Dallas, Texas 12/26/2013 (FINANCIALSTRENDS) – Eli Lilly & Co. (NYSE:LLY) is a major drug maker which is into development and manufacture of pharma products for both animals and humans. It has manufacturing operations spread across 17 countries of the world and its products are sold across 130 countries. Its product buckets include “neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products.” Over the trailing 12 months, it has managed to post net sales of $23.26 billion and gather net income of $4.78 billion.
Strong Pipeline Of New Drugs
More importantly, its line up of target drugs is impressive with many drugs like “Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabaluma” being made to go through various stages of clinical trials with the aim of getting them through FDA approval process.
New Drug Application
Earlier this month Eli Lilly & Co. (NYSE:LLY) announced that it has filed a new drug application in collaboration with Boehringer Ingelheim for getting FDA go ahead for target drug insulin glargine product. This application by the drug maker in U.S follows its application with European Medicines Agency with its “Marketing Authorisation Application”. It is also been announced that the U.S. Food and Drug Administration (FDA) has indeed accepted their combined application for target drug codenamed LY2963016 which is expected to work on the lines of insulin.
New Diabetic Drug
The application describes the target drug LY2963016 in its application as a unique “insulin glargine” based solution which when fully developed is expected to cure type 1 and type 2 diabetes. As part of the NDA, the tag team of Eli Lilly & Co. (NYSE:LLY) and Boehringer Ingelheim will test out the relative performance of the target drug in relation to “pharmacokinetic and pharmacodynamic studies”. To secure the NDA acceptance the drug makers were based on positive results from its Phase III studies and tests conducted on type 1 and type 2 diabetes patients.
Commenting about the NDA submission,Gwen Krivi, Ph.D, who is the vice president of Eli Lilly & Co. (NYSE:LLY) diabetes product development team has been quoted as saying, “The U.S. regulatory submission for our new insulin glargine product demonstrates our progress in bringing another option to the millions of Americans with diabetes who require long-acting insulin as an integral part of their treatment plan. This submission of the NDA for this product helps us realize the goal of the Lilly-Boehringer Ingelheim Diabetes alliance, which is to leverage our combined expertise to develop important treatments for people with diabetes.”
Stock Market Performance
Eli Lilly & Co. (NYSE:LLY) stock has scripted a good 3.09 percent increase in its market value in the past week. This S&P 500 index tracked stock has been under pressure to perform at the markets over the past one quarter. It has managed to post net loss of 0.96 percent in the past one month and has shed more than 3.5 percent in the past quarter. In the past one year, the stock has been range bound between $47.09 and $57.37 and over all its share holders have gained by 6.3 percent in the same one year period. At current price point of $50.74 per share, the stock has managed to gain momentum to levels which have taken it to just 11.5 percent below its 52 week high price mark.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.